Moderna’s First mRNA-359 Personalized Cancer Vaccine Commemorative Vial
Moderna’s high-stakes pivot toward personalized mRNA cancer vaccines, developed alongside Merck, has reshaped the company’s clinical trajectory following pandemic-era revenue declines. Utilizing messenger RNA platforms to target patient-specific neoantigens, this … Read More